Transplantation
Conference Coverage
Isatuximab Quadruplet Approval Could Change the Landscape for Treating Myeloma
Findings of phase 3 IMROZ trial demonstrated the efficacy of Isa-VRd, a four-drug combo, in treating patients newly diagnosed with myeloma.
From the Journals
Extended virus shedding after COVID-19 in some patients with cancer
Some patients, including stem cell transplant and CAR T recipients, may require extended periods of isolation.
Feature
Patient-focused precautions, testing help blunt pandemic effects on heme-onc unit
Multiple factors helped keep the anticipated COVID-19 surge manageable at the hematologic oncology service of Levine Cancer Institute.
From the Journals
REACH2: Ruxolitinib outperformed control treatment for refractory acute GVHD
Ruxolitinib was significantly more effective against acute graft-versus-host disease but produced more thrombocytopenia than did control treatment...
Latest News
Phase 2 study shows regimen benefit with dasatinib in Ph+ALL therapy
From the Journals
CAR T-cell therapy may worsen mental health in some patients
From the Journals
Several factors may drive recent improvements in allo-HCT outcomes
Patients transplanted in recent years were older and sicker at baseline but had better outcomes than did patients transplanted in the mid-2000s....
Conference Coverage
PT-Cy bests conventional GVHD prophylaxis
ORLANDO – Rates of progression/relapse, progression-free survival, and overall survival were similar between posttransplant cyclophosphamide and...
Conference Coverage
Myeloma patients over age 70 can benefit from auto-HC transplant
ORLANDO – Researchers said all myeloma patients should be referred a transplant center, regardless of age.
From the Journals
Case-control study IDs several novel risk factors of post-HCT melanoma
Feature
First NCCN guideline on hematopoietic cell transplantation focuses on GVHD
Diagnosis and management of both acute and chronic graft-versus-host disease is at the core of the recommendations.